Not Yet RecruitingNot Applicable

the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines

China600 participantsStarted 2026-01-30

Plain-language summary

This study evaluated the antibody persistence of Chinese children five years after they received four doses of sIPV, two doses of MMR vaccine and one dose of HepA-L vaccine.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants in the NCT04638985 or NCT04636827, and who have completed the vaccination of designated batch numbers of sIPV, MMR or HepA-L vaccines; * The time window from the day of enrollment to the date when the participants received the fourth dose of sIPV vaccine, the second dose of MMR vaccine, or the first dose of HepA-L vaccine was 60 to 66 months. * The informed consent form shall be signed by the participant or his/her legal guardian and dated. Exclusion Criteria: * None.

What they're measuring

seropositive rates of antibodies against poliovirus

Timeframe: 5 years after the four doses of sIPV immunization

seropositive rates of antibodies against measles, rubella, mumps

Timeframe: 5 years after the two doses of MMR immunization

seropositive rates of antibodies against hepatitis A

Timeframe: 5 years after the one doses of HepA-L immunization

Trial details

NCT IDNCT07338851

SponsorChina National Biotec Group Company Limited

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-12-31

Contact for this trial

Weijun Hu

029-82221350 huweijun0828@163.com

View on ClinicalTrials.gov More Polio trials